Live Microbiota Therapy Prevents Recurrent CDI in Older Adults with Comorbidity

New data presented at ACG 2023 showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.

Related Keywords

Canada ,Vancouver ,British Columbia ,Andrew Skinner ,Cirlea Warren ,American College Of Gastroenterology ,Loyola University ,University Of Virginia ,American College ,Scientific Meeting ,Fecal Microbiota ,Older Participants With Recurrent Clostridioides ,Underlying Comorbidities ,First Live Microbiota Treatment ,Microbiome Based Therapies ,Treating Recurrent ,Spreferring ,Rcdi ,C Difficile ,Recurrent ,Microbiota ,Acg 2023 ,Data ,Phase 3 ,